Drug Design of Cyclin-Dependent Kinase 2 Inhibitor for Melanoma from Traditional Chinese Medicine

被引:11
作者
Tang, Hsin-Chieh [1 ]
Chen, Calvin Yu-Chian [1 ,2 ,3 ,4 ]
机构
[1] Asia Univ, Dept Biomed Informat, Taichung 41354, Taiwan
[2] China Med Univ, Dept Med, Taichung 40402, Taiwan
[3] China Med Univ, Res Ctr Chinese Med & Acupuncture, Taichung 40402, Taiwan
[4] China Med Univ Hosp, Dept Med Res, Human Genet Ctr, Taichung 40447, Taiwan
关键词
CELL-CYCLE; PROTEIN; CANCER; RESISTANCE; EXPRESSION; POTENT; CDK2; GENE; P21; SIMULATION;
D O I
10.1155/2014/798742
中图分类号
Q81 [生物工程学(生物技术)]; Q93 [微生物学];
学科分类号
071005 ; 0836 ; 090102 ; 100705 ;
摘要
One has found an important cell cycle controller. This guard can decide the cell cycle toward proliferation or quiescence. Cyclin-dependent kinase 2 (CDK2) is a unique target among the CDK family in melanoma therapy. We attempted to find out TCM compounds from TCM Database@Taiwan that have the ability to inhibit the activity of CDK2 by systems biology. We selected Tetrahydropalmatine, Reserpiline, and (+)-Corydaline as the candidates by docking and screening results for further survey. We utilized support vectormachine (SVM), multiple linear regression (MLR) models and Bayesian network for validation of predicted activity. By overall analysis of docking results, predicted activity, and molecular dynamics (MD) simulation, we could conclude that Tetrahydropalmatine, Reserpiline, and (+)-Corydaline had better binding affinity than the control. All of them had the ability to inhibit the activity of CDK2 and might have the opportunity to be applied in melanoma therapy.
引用
收藏
页数:17
相关论文
共 50 条
  • [21] Targeting cyclin-dependent kinase 4/6 as a therapeutic approach for mucosal melanoma
    Shi, Chao-ji
    Xu, Sheng-ming
    Han, Yong
    Zhou, Rong
    Zhang, Zhi-yuan
    MELANOMA RESEARCH, 2021, 31 (06) : 495 - 503
  • [22] FMN2 is a novel regulator of the cyclin-dependent kinase inhibitor p21
    Yamada, Kayo
    Ono, Motoharu
    Bensaddek, Dalila
    Lamond, Angus I.
    Rocha, Sonia
    CELL CYCLE, 2013, 12 (15) : 2348 - 2354
  • [23] Cyclin-dependent kinase inhibitor 2B regulates efferocytosis and atherosclerosis
    Kojima, Yoko
    Downing, Kelly
    Kundu, Ramendra
    Miller, Clint
    Dewey, Frederick
    Lancero, Hope
    Raaz, Uwe
    Perisic, Ljubica
    Hedin, Ulf
    Schadt, Eric
    Maegdefessel, Lars
    Quertermous, Tom
    Leeper, Nicholas J.
    JOURNAL OF CLINICAL INVESTIGATION, 2014, 124 (03) : 1083 - 1097
  • [24] Cyclin-Dependent Kinase Inhibitor Dinaciclib Interacts with the Acetyl-Lysine Recognition Site of Bromodomains
    Martin, Mathew P.
    Olesen, Sanne H.
    Georg, Gunda I.
    Schoenbrunn, Ernst
    ACS CHEMICAL BIOLOGY, 2013, 8 (11) : 2360 - 2365
  • [25] Global trends and hotspots in Cyclin-dependent Kinase Subunit 2 research from 1999 to 2022: A bibliometric and visualized analysis
    Li, Ziteng
    Chen, Yuanzhen
    Zhang, Bo
    Xie, Liangyu
    Shi, Bin
    MEDICINE, 2023, 102 (48) : E36319
  • [26] Characterization of an A-type cyclin-dependent kinase gene from Dendrobium candidum
    Zhang, Gang
    Song, Chao
    Zhao, Ming-Ming
    Li, Biao
    Guo, Shun-Xing
    BIOLOGIA, 2012, 67 (02) : 360 - 368
  • [27] Lessons Learned from Past Cyclin-Dependent Kinase Drug Discovery Efforts
    Xie, Zhouling
    Hou, Shuzeng
    Yang, Xiaoxiao
    Duan, Yajun
    Han, Jihong
    Wang, Qin
    Liao, Chenzhong
    JOURNAL OF MEDICINAL CHEMISTRY, 2022, 65 (09) : 6356 - 6389
  • [28] Analysis of cyclin-dependent kinase inhibitor 1B mutation in Han Chinese women with premature ovarian failure
    Wang, Binbin
    Ni, Feng
    Li, Lin
    Wei, Zhaolian
    Zhu, Xianglong
    Wang, Jing
    Cao, Yunxia
    Ma, Xu
    REPRODUCTIVE BIOMEDICINE ONLINE, 2010, 21 (02) : 212 - 214
  • [29] Knockdown of Cyclin-Dependent Kinase Inhibitor 3 Inhibits Proliferation and Invasion in Human Gastric Cancer Cells
    Li, Yan
    Ji, Shan
    Fu, Li-Ye
    Jiang, Tao
    Wu, Di
    Meng, Fan-Dong
    ONCOLOGY RESEARCH, 2017, 25 (05) : 721 - 731
  • [30] Design, synthesis, and primary activity assays of baicalein derivatives as cyclin-dependent kinase 1 inhibitors
    Mou, Jiajia
    Qiu, Shuang
    Chen, Danghui
    Deng, Yanru
    Tekleab, Teka
    CHEMICAL BIOLOGY & DRUG DESIGN, 2021, 98 (04) : 639 - 654